Mercadante Sebastiano, Marchetti Paolo, Cuomo Arturo, Mammucari Massimo, Caraceni Augusto
Anesthesia and Intensive Care & Pain Relief and Supportive Care, La Maddalena, Italy.
Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Via San Lorenzo 312, 90146, Palermo, Italy.
Support Care Cancer. 2016 Feb;24(2):961-968. doi: 10.1007/s00520-015-2951-y. Epub 2015 Oct 5.
Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.
关于突破性癌痛（BTcP）的定义、流行病学、药物治疗选择、药物剂量以及如何在新型芬太尼产品中为BTcP选择药物，存在诸多争议。一个专家小组对现有数据进行了严格评估以提供建议。应使用一种诊断BTcP的算法，随后进行仔细评估。芬太尼产品在对抗BTcP的时间模式方面具有疗效和快速起效的特点。用于背景疼痛的阿片类药物剂量应指导芬太尼产品剂量的选择。芬太尼产品的选择应基于个体临床情况。
